Catalog No.
PHG13401
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MCL1 (Arg6-Ile328).
Applications
ELISA, IHC, WB
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000 |
Target
mcl1/EAT,Bcl2-L-3,Induced myeloid leukemia cell differentiation protein Mcl-1,Bcl-2-like protein 3,BCL2L3,Bcl-2-related protein EAT/mcl1,MCL1
Purification
Purified by antigen affinity column.
Accession
Q07820
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note
For research use only.
BCAP31 is involved in modulating colorectal cancer cell proliferation via the Emerin/β-catenin axis., PMID:35716785
Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death., PMID:35805980
Diverse actions of sirtuin-1 on ovulatory genes and cell death pathways in human granulosa cells., PMID:35840944
Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease., PMID:35850051
Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma., PMID:35884390
The promoting effect of neutrophil-derived BAFF molecule on the proliferation and life span of CAL-27 oral squamous carcinoma cells., PMID:35933760
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors., PMID:35979386
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins., PMID:35993382
MicroRNA-148a induces apoptosis and prevents angiogenesis with bevacizumab in colon cancer through direct inhibition of ROCK1/c-Met via HIF-1α under hypoxia., PMID:35997665
Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective., PMID:36154801
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics., PMID:36184661
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL., PMID:36287248
Resistance to targeted therapies in acute myeloid leukemia., PMID:36318439
Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition., PMID:36367857
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax., PMID:36485153
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study., PMID:36594167
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer., PMID:36622698
MAPK Cascade Signaling Is Involved in α-MMC Induced Growth Inhibition of Multiple Myeloma MM.1S Cells via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis In Vitro., PMID:36678620
AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas., PMID:37074033
PKM2/STAT1-mediated PD-L1 upregulation on neutrophils during sepsis promotes neutrophil organ accumulation by serving an anti-apoptotic role., PMID:37131151
Intrinsically determined turnover underlies broad heterogeneity in plasma-cell lifespan., PMID:37164016
Transcriptomic analysis of neutrophil apoptosis induced by diffuse large B-cell lymphoma unveils a potential role in neutropenia., PMID:37266765
An updated patent review of Mcl-1 inhibitors (2020-2022)., PMID:37293764
The RNA binding proteins TIA1 and TIAL1 promote Mcl1 mRNA translation to protect germinal center responses from apoptosis., PMID:37474714
Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy., PMID:37481672
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models., PMID:37548343
Soybean lectin-triggered IL-6 secretion induces autophagy to kill intracellular mycobacteria through P2RX7 dependent activation of the JAK2/STAT3/Mcl-1 pathway., PMID:37716189
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity., PMID:37793852
Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1., PMID:37896184
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas., PMID:38386805
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells., PMID:38582955
Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells., PMID:38730731
Development of chromone-thiazolidine-2,4-dione Knoevenagel conjugates as apoptosis inducing agents., PMID:38909705
Tirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells., PMID:38967656
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
The multifaceted potential of TPT1 as biomarker and therapeutic target., PMID:39397949
MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC., PMID:39543744
JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL., PMID:39570282
Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies., PMID:39596160
Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy., PMID:39632279
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442
Antisense oligonucleotides-based approaches for the treatment of multiple myeloma., PMID:39732226
Elevated MCL1 expression drives esophageal squamous cell carcinoma stemness and induces resistance to radiotherapy., PMID:39831242
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan., PMID:39931207
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy., PMID:40113751
Evaluating Apoptotic Gene Efficiency for CHO Culture Performance Using Targeted Integration., PMID:40268279
Overexpression of Tgm2 in Chinese Hamster Ovary Cells Enhances Recombinant Monoclonal Antibody Expression and Promotes Cell Proliferation through Reduction of Apoptosis., PMID:40327404
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors., PMID:40442785
For research use only. Not for human or drug use.
